Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 19;3(1):vdab169. doi: 10.1093/noajnl/vdab169

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Clinical experience of DIPG patients receiving German-sourced ONC201 (GsONC201). (A) Kaplan–Meier survival analysis reporting median overall survival for all patients receiving GsONC201 compared to brainstem glioma patients reported by Chen et al.² (18 months vs 9.2 months, P = .0007 Wilcoxon [Gehan–Breslow] test, 95% CI 1.292–4.153; P = .0017 Log-rank [Mantel–Cox] 95% CI 1.447–4.990). (B) Kaplan–Meier survival analysis reporting median overall survival when initiated following initial radiotherapy. (C) Kaplan–Meier survival analysis reporting median recurrent overall survival. (D) Analysis of median overall survival for patients receiving GsONC201 and concomitant proton pump inhibitors (PPI) compared to GsONC201 patients who did not use PPIs (17 vs 22 months, P = .7946 Log-rank [Mantel–Cox] test, 95% CI 0.3151–2.507). (E) Kaplan–Meier survival analysis reporting median OS survival for patients who received GsONC201 and underwent reirradiation compared to patients who received GsONC201 and did not have reirradiation (12 vs 22 months, P = .0120, Wilcoxon [Gehan–Breslow] test, 95% CI 0.7709–6.143). (F) Summary of survival data.